Photo courtesy of iStockphoto, Vasiliy Yakobchuk
Xenazine (tetrabenazine), product of Prestwick Pharmaceuticals, Inc. (Washington, D.C.) is the first drug approved by the FDA for the treatment of chorea - the jerky, involuntary movement - in people with Huntington's disease.

Xenazine decreases the amount of dopamine available to work at relevant synapses in the brain. Dopamine is a chemical that communicates between certain nerve cells in the brain. In patients with Huntington's disease, this system is overactive and results in the abnormal movements called chorea. Xenazine decreases the amount of dopamine available to interact with certain nerve cells, thereby decreasing the involuntary movements.

A rare, hereditary neurological disorder affecting about 1 in 10,000 people in the United States, Huntington's disease resulting from the degeneration of the brain cells, is characterized by uncontrolled movements, loss of intellectual faculties, and emotional disturbance.

No other drug for chorea is approved in the United States. But Xenazine has serious side effects reported including insomnia, depression, drowsiness, restlessness and nausea. But has been shown to decrease chorea, thereby improving the quality of life in Huntington's disease patients.

Read more from the FDA News.

See full article.

Related Entries:

Emory Research Identifies Neurodegeneration Cause in Huntington's Disease - 09 June 2006

Green Tea/Green Tea Extracts, May Slow the Progression of Huntington's Disease - 12 September 2006

Novel Device for Cervical Degenerative Disc Disease Treatment, Approved by the FDA - 20 July 2007

Tetrabenazine (TBZ) Protects Brain Cells in Huntington's Disease Model - 26 July 2007

Contents of this feed are a property of Creative Weblogging Limited and are protected by copyright laws. Violations will be prosecuted. Please email us if you'd like to use this feed for non-commercial activities at feeds - at - creative-weblogging.com.